Literature DB >> 8625250

Validation of a multidimensional evaluation scale for use in elderly cancer patients.

S Monfardini1, L Ferrucci, L Fratino, I del Lungo, D Serraino, V Zagonel.   

Abstract

BACKGROUND: Although aging is one of the most important risk factors for cancer, elderly patients tend to be excluded from cancer clinical trials, only on the basis of chronologic age. Performance Status (PS) has been used widely to select adult patients for entry into clinical trials, but it does not include a comprehensive evaluation of various age-related factors in the elderly. This study was designed to assess the reliability and validity of a multidimensional geriatric assessment protocol for elderly patients with cancer.
METHODS: Thirty consecutive elderly patients (> or = 65 years), diagnosed with hematologic neoplasia or solid tumors and undergoing chemotherapy or radiotherapy, were given a specifically structured multidimensional questionnaire (MACE) three times during one week by two different physicians. MACE was intended to collect information on demographics, socioeconomic status, cognitive status, depression, physical performance, disability, and tumor characteristics. In parallel with MACE, information was collected by means of the Sickness Impact Profile (SIP).
RESULTS: Both for inter-rater and test-retest reliability, the values of the intraclass correlation coefficient (ICC) were generally higher than 0.7. Disability, cognitive status, depressive symptoms, and the number of days spent in bed sick in the last two weeks were markedly correlated with the global, physical, and social SIP score. Disability alone explained 70% of the variance in the SIP global score, 83% of the variance in the SIP physical score, and 45% of the variance in the SIP psychosocial score. MACE proved to be applicable in a reasonable amount of time (around 30 minutes) for a medical oncology ward.
CONCLUSIONS: These data indicate that this structured evaluation of functional status is feasible and reliable. MACE is therefore proposed as a clinical research tool to avoid arbitrary decisions on patient selection for enrollment in clinical trials, to favor uniform monitoring of treatment, and to allow a better comparison of results.

Entities:  

Mesh:

Year:  1996        PMID: 8625250     DOI: 10.1002/(SICI)1097-0142(19960115)77:2<395::AID-CNCR24>3.0.CO;2-W

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

Review 1.  Drug therapy for gynaecological cancer in older women.

Authors:  R E van Rijswijk; J B Vermorken
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

Review 2.  Adjuvant chemotherapy for breast cancer in older women: emerging evidence to aid in decision making.

Authors:  Gretchen Kimmick
Journal:  Curr Treat Options Oncol       Date:  2011-09

3.  Senior adult oncology.

Authors:  Arti Hurria; Ilene S Browner; Harvey Jay Cohen; Crystal S Denlinger; Mollie deShazo; Martine Extermann; Apar Kishor P Ganti; Jimmie C Holland; Holly M Holmes; Mohana B Karlekar; Nancy L Keating; June McKoy; Bruno C Medeiros; Ewa Mrozek; Tracey O'Connor; Stephen H Petersdorf; Hope S Rugo; Rebecca A Silliman; William P Tew; Louise C Walter; Alva B Weir; Tanya Wildes
Journal:  J Natl Compr Canc Netw       Date:  2012-02       Impact factor: 11.908

4.  Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma.

Authors:  Michele Spina; Monica Balzarotti; Lilj Uziel; Andrés José Marìa Ferreri; Lucia Fratino; Massimo Magagnoli; Renato Talamini; Annalisa Giacalone; Elena Ravaioli; Emanuela Chimienti; Massimiliano Berretta; Arben Lleshi; Armando Santoro; Umberto Tirelli
Journal:  Oncologist       Date:  2012-05-18

Review 5.  Systemic therapies for metastatic renal cell carcinoma in older adults.

Authors:  Sumanta K Pal; Ari Vanderwalde; Arti Hurria; Robert A Figlin
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

6.  A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer.

Authors:  Kenji Hashimoto; Kan Yonemori; Chikako Shimizu; Akihiro Hirakawa; Harukaze Yamamoto; Makiko Ono; Taizo Hirata; Tsutomu Kouno; Kenji Tamura; Noriyuki Katsumata; Masashi Ando; Yasuhiro Fujiwara
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

7.  Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401.

Authors:  Arti Hurria; Constance T Cirrincione; Hyman B Muss; Alice B Kornblith; William Barry; Andrew S Artz; Linda Schmieder; Rafat Ansari; William P Tew; Douglas Weckstein; Jeffrey Kirshner; Kayo Togawa; Kurt Hansen; Vani Katheria; Richard Stone; Ilene Galinsky; John Postiglione; Harvey Jay Cohen
Journal:  J Clin Oncol       Date:  2011-02-28       Impact factor: 44.544

Review 8.  Assessment and treatment relevance in elderly glioblastoma patients.

Authors:  Luc Bauchet; Sonia Zouaoui; Amélie Darlix; Nicolas Menjot de Champfleur; Ernestine Ferreira; Michel Fabbro; Christine Kerr; Luc Taillandier
Journal:  Neuro Oncol       Date:  2014-05-02       Impact factor: 12.300

Review 9.  Treatment and outcomes for elderly patients with small cell lung cancer.

Authors:  R J Stephens; D H Johnson
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

10.  Doublet chemotherapy in the elderly patient with ovarian cancer.

Authors:  Min Y Teo; Derek G Power; William P Tew; Stuart M Lichtman
Journal:  Oncologist       Date:  2012-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.